Liraglutide long -term use, a substance that helps reduce blood sugar levels in patients with type 2 diabetes, can have a deteriorating effect on beta cells of insulin producers, leading to an increase in levels ofBlood sugar, according to a study conducted in mice implanted with human insulin producing cells of a team of scientists from the Karolinska Institute, in Sweden, and the University of Miami, in the United States.
The researchers, whose work is revealed in an article published in 'Cell Metabolism', alert the possible consequences of this popular therapeutic form, the liraglutidPeptide similar to glucagon-1 (LPG-1), naturally secreted by the intestine after eating to help stabilize blood sugar levels.
Blood sugar suppressors are commonly used in the form of analogues of the GLP-1 hormone in the treatment of type 2 diabetes, since they stimulate the glucose response of the beta cells of the pancreas to secrete more insulin.Now, there is evidence that liraglutide therapy is effective at least in the short term, since it produces an initial reduction in blood sugar, many patients do not respond to treatment and some even show adverse reactions such as nausea, vomiting and vomiting anddiarrhea.
To study the long -term effects of the therapy of the Incartin, which had not previously been analyzed, the authors of this research worked with humanized mice, generated by the transplantation of human insulin producing cells in the anterior chamber of the eye.The rodents received daily doses of liraglutida for more than 250 days, during which scientists were able to control how beta cells of the pancreas were affected.
The results showed an initial improvement in insulin producing cells, followed by gradual exhaustion, with reduction in insulin secretion in response to glucose, something that researchers indicate, it was unexpected."Given the lack of clinical studies on the long -term effect of these drugs in patients with diabetes, it is a very important discovery," says Midhat Abdulreda, a researcher at the Diabetes Research Institute of the Miller Medicine School of MedicineMiami University.
"We also have to take into account these results before prescribing LPG-1 analogues for the suppression of blood sugar when long-term treatment regimes for patients are planned," says Per-OLOF Berggren, a professor at the Research CenterRolf Luft for diabetes and endocrinology in the Department of Molecular Medicine and Surgery of the Karolinska Institute, Sweden."Our study shows, in general, the way to carry out in vivo studies of the long -term effects of drugs on human insulin producing cells, which should be very important for the pharmaceutical industry," he concludes.
